-
Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction
Juni, R. P., Al-Shama, R., Kuster, D. W. D., van der Velden, J., Hamer, H. M., Vervloet, M. G., Eringa, E. C., Koolwijk, P. & van Hinsbergh, V. W. M., May 2021, In: Kidney international. 99, 5, p. 1088-1101 14 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease
Ursem, S. R., Heijboer, A. C., D'Haese, P. C., Behets, G. J., Cavalier, E., Vervloet, M. G. & Evenepoel, P., May 2021, In: Kidney international. 99, 5, p. 1173-1178 6 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease
van der Aart-van der Beek, A. B., Koomen, J. V., Dekkers, C. C. J., Barbour, S. J., Boulton, D. W., Gansevoort, R. T., Greasley, P. J., Abdul Gafor, A. H., Laverman, G. D., Li, Q., Lim, S. K., Stevens, J., Vervloet, M. G., Singh, S., Cattran, D. C., Reich, H. N., Cherney, D. Z. I. & Heerspink, H. J. L., 1 Apr 2021, In: Clinical pharmacokinetics. 60, 4, p. 517-525 9 p.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
